Literature DB >> 34558299

PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.

Arrush Choudhary1,2, D Marshall Brinkley1, Sepideh Besharati3, Wouter C Meijers1,2, James B Atkinson4, Kaushik Amancherla1,2, Qingfeng Zhu3, Shi Huang5, Lee S Nguyen6,7,8, Joe-Elie Salem1,2,6,7, Enrico Ammirati9, JoAnn Lindenfeld1, Robert A Anders3, Javid Moslehi1,2.   

Abstract

Entities:  

Keywords:  biopsy; graft rejection; humans; myocarditis; upregulation

Mesh：

Substances：

Year:  2021        PMID： 34558299      PMCID： PMC8608373          DOI： 10.1161/CIRCHEARTFAILURE.121.008563

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   10.447


× No keyword cloud information.
  5 in total

1.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

2.  PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Authors:  Joel C Sunshine; Peter L Nguyen; Genevieve J Kaunitz; Tricia R Cottrell; Sneha Berry; Jessica Esandrio; Haiying Xu; Aleksandra Ogurtsova; Karen B Bleich; Toby C Cornish; Evan J Lipson; Robert A Anders; Janis M Taube
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

3.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

4.  Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

Authors:  S Ugurel; D Schadendorf; K Horny; A Sucker; S Schramm; J Utikal; C Pföhler; R Herbst; B Schilling; C Blank; J C Becker; A Paschen; L Zimmer; E Livingstone; P A Horn; V Rebmann
Journal:  Ann Oncol       Date:  2020-01       Impact factor: 32.976

Review 5.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Authors:  Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808
  5 in total
  1 in total

1.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.